Details:
Sanofi, together with SIRION will develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency.
Lead Product(s): AAV capsid-gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 23, 2021